Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.49 |
| ▸ | MAOA | P21397 | 10/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284643 | 0.81 | MAOB (0.50) | MAOBMAOAHRH3ITGB3ITGA2B | |
| SCHEMBL4288580 | 0.80 | MAOA (0.51) | MAOBMAOA | |
| SCHEMBL4281703 | 0.80 | RAB9A (0.44) | HRH3 | |
| SCHEMBL4752778 | 0.80 | RAB9A (0.44) | HRH3 | |
| SCHEMBL10681764 | 0.79 | MAOB (0.54) | MAOBMAOAHRH3 | |
| Hydrochloric Acid SCHEMBL4289106 | 0.78 | TSHR (0.41) | MAOBITGB3ITGA2B | |
| SCHEMBL4290237 | 0.78 | MAOB (0.51) | MAOBMAOA | |
| SCHEMBL4294977 | 0.78 | NPC1 (0.45) | HRH3 | |
| SCHEMBL3493396 | 0.77 | TEAD1 (0.46) | — | |
| SCHEMBL4291445 | 0.77 | TSHR (0.41) | MAOBMAOAITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MAOB 550/4885MAOA 660/4885HRH3 1248/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MAOB 550/4885MAOA 660/4885HRH3 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.